NASDAQ:LENS - Presbia Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.91 +0.18 (+24.66 %)
(As of 11/15/2018 01:13 AM ET)
Previous Close$0.73
Today's Range$0.68 - $1.65
52-Week Range$0.64 - $7.14
Volume939,800 shs
Average Volume24,943 shs
Market Capitalization$12.70 million
P/E RatioN/A
Dividend YieldN/A
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

Receive LENS News and Ratings via Email

Sign-up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Current SymbolNASDAQ:LENS
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio2.15
Quick Ratio2.11


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales1,561.56
Cash FlowN/A
Price / CashN/A
Book Value$0.18 per share
Price / Book5.06


EPS (Most Recent Fiscal Year)N/A
Net Income$-16,990,000.00
Net MarginsN/A
Return on Equity-334.04%
Return on Assets-198.59%


Outstanding Shares17,160,000
Market Cap$12.70 million
OptionableNot Optionable

Presbia (NASDAQ:LENS) Frequently Asked Questions

What is Presbia's stock symbol?

Presbia trades on the NASDAQ under the ticker symbol "LENS."

How were Presbia's earnings last quarter?

Presbia PLC (NASDAQ:LENS) issued its earnings results on Friday, August, 12th. The medical instruments supplier reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.07. The medical instruments supplier had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.04 million. View Presbia's Earnings History.

When is Presbia's next earnings date?

Presbia is scheduled to release their next quarterly earnings announcement on Friday, November 16th 2018. View Earnings Estimates for Presbia.

What price target have analysts set for LENS?

1 brokers have issued twelve-month price targets for Presbia's shares. Their predictions range from $6.00 to $6.00. On average, they expect Presbia's share price to reach $6.00 in the next year. This suggests a possible upside of 559.3% from the stock's current price. View Analyst Price Targets for Presbia.

What is the consensus analysts' recommendation for Presbia?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Presbia in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Presbia.

What are Wall Street analysts saying about Presbia stock?

Here are some recent quotes from research analysts about Presbia stock:
  • 1. According to Zacks Investment Research, "Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company's product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. " (9/27/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a discounted cash flow-based net present value (NPV) approach to value Presbia. This yields a total value of $160M for the Flexivue Microlens product, using a 20% discount rate, 50% manufacturing and marketing offset, and a 12.5% tax rate as Presbia is domiciled in Ireland." (8/27/2018)

Has Presbia been receiving favorable news coverage?

News headlines about LENS stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Presbia earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Presbia's key competitors?

Who are Presbia's key executives?

Presbia's management team includes the folowing people:
  • Mr. Vladimir Feingold, Consultant (Age 69)
  • Mr. Mark T. Yung, CEO & Chairman (Age 44)
  • Mr. Richard T. Fogarty, Chief Accounting Officer, VP of Fin. & Sec. (Age 67)
  • Ms. Casey Jean Lind, Chief Operating Officer (Age 56)
  • Ms. Marie Cha, Director of Direct Response Marketing

When did Presbia IPO?

(LENS) raised $50 million in an IPO on Thursday, January 29th 2015. The company issued 4,200,000 shares at a price of $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO.

How do I buy shares of Presbia?

Shares of LENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Presbia's stock price today?

One share of LENS stock can currently be purchased for approximately $0.91.

How big of a company is Presbia?

Presbia has a market capitalization of $12.70 million and generates $10,000.00 in revenue each year. Presbia employs 24 workers across the globe.

What is Presbia's official website?

The official website for Presbia is

How can I contact Presbia?

Presbia's mailing address is SANDYFORD OFFICE CENTRE SUITE 7 17 CORRIG ROAD, DUBLIN 18 L2, . The medical instruments supplier can be reached via phone at 353-551-1487.

MarketBeat Community Rating for Presbia (NASDAQ LENS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about Presbia and other stocks. Vote "Outperform" if you believe LENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel